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Introduction
In roughly one third of patients with schizophrenia spectrum and other psychotic disorders (SSD), response is not achieved after two consecutive antipsychotic trials 1 . These patients are considered to have (relatively) treatment resistant schizophrenia (TRS) 2, 3 . TRS in turn is defined as achieving insufficient treatment response (i.e. persisting positive symptoms of at least moderate severity) after two or more antipsychotic trials from at least two different J o u r n a l P r e -p r o o f chemical classes at a recognized therapeutic dosage used for at least six weeks 4, 5 .
Guidelines of the World Federation of Societies of Biological Psychiatry (WFSBP) and of other organizations advise that clozapine (CLZ) should be initiated in patients with TRS 6, 7 . CLZ is the only registered drug for TRS and one of the most effective antipsychotics 8 , with 30 to 60% of TRS patients responding to CLZ treatment [9] [10] [11] . In addition, a recent meta-analysis demonstrated that CLZ, compared with second-generation antipsychotics, was associated with lower (re)hospitalization and lower all-cause discontinuation rates, as well as better outcomes regarding overall symptoms 12 . In clinical practice, WFSBP guidelines are not always followed and merely 30% of TRS patients receive CLZ treatment 13 . The delay in initiation of CLZ pharmacotherapy, defined as the moment of meeting TRS criteria until initiating CLZ pharmacotherapy, is approximately 4-6 years [14] [15] [16] . Delays in adequate treatment of SSD are clinically undesirable as increasing numbers of psychotic exacerbations impair daily and occupational functioning, thus negatively influencing quality of life of patients with SSD 17, 18 .
Possible reasons for the underutilization of CLZ are the absence of personal prescribing experience by psychiatrists and psychiatry trainees, as well as patients' and mental health professionals' concerns about side effects and blood monitoring [19] [20] [21] . Although the majority of psychiatrists and psychiatry trainees are aware of the effectiveness of CLZ 19, 20 , many believe the possible complications and risks outweigh the benefits 22 . Importantly, clinicians might decide to initiate CLZ treatment with less of a delay when they have information at hand indicating what patient characteristics increase the odds of treatment response. Recently, a systematic review on biological predictors (e.g. neuroimaging, genetics and biochemistry) concluded that there are currently no biological predictors with sufficient accuracy available 23 .
The aim of the current study was therefore to focus not on biological predictors, but on demographical and, clinical and biochemical patient characteristics as potential predictors of J o u r n a l P r e -p r o o f CLZ response. To that end, we performed a systematic review and meta-analysis to examine which of those characteristics are most strongly associated with CLZ response.
Methods

Search strategy and study selection
A systematic literature search was performed in the databases 'PubMed' and 'Embase' to find all studies investigating predictors of CLZ pharmacotherapy response in SSD patients. The following search terms were used: 'schizophreni*' AND 'clozapine' AND 'marker*' OR 'predict*' AND 'respon*'. The full search terms and details can be found in the Appendix, supplementary 
Assessment of treatment response
Response can be measured by using several rating scales assessing baseline symptoms and improvement of symptoms after starting a new treatment. The Positive And Negative Syndrome Scale (PANSS) and Brief Psychiatric Rating Scale (BPRS) are frequently used to measure response to antipsychotic drug treatment 24 . The PANSS is a semi-structured interview with 30 items rated on a 7-point scale, with 1 being "absent" and 7 being "extreme" 25 . The BPRS is based on clinical observations and patient self-report. It has 18 items and is also rated on a 7point scale, 1 being "not present" and 7 being "extremely severe" 25 . Both scales have been validated and show robust reliability and sensitivity 24 . Results of the PANSS and BPRS can be translated to the Clinical Global Impressions (CGI) scale to gain a better understanding of their clinical significance 24, 26 . The CGI-Severity (CGI-S) scale rates the current severity of illness on a 7-point scale, 1 meaning "normal, not at all ill" and 7 meaning "among the most severely ill" 27 .
In all scales, a higher score is related to more severe illness. A reduction of 10 points in BPRS and 15 points in PANSS scores over time translate into a decrease of one point on the CGI-S 26 .
Since these scales (BPRS, PANSS, CGI) have been validated for SSD patients and are intercorrelated all were allowed as response data input for the current meta-analyses. We thus conceded that the articles included in the meta-analysis used disparate rating scales for response.
Statistical analyses
We divided the patient characteristics into the articles in several categories; 1) Demographic and general factors; 2) Clinical factors and 3) Biochemical factors. We set a threshold of at least 3 articles per potential predictor to perform random-effects meta-analyses, because the J o u r n a l P r e -p r o o f included studies were expected not to be functionally equivalent and a common effect size across them could not be assumed 28 . The test statistics were generated with the program 'Comprehensive Meta-Analysis' version 3.3.070 (2014) from BioStat. Alpha was set at 0.05.
Hedges' g was used as a measurement of effect size. To quantify the degree of heterogeneity across the included studies we included, Cochran's Q test and the I 2 statistic were used. The
Cochran's Q test was used to determine whether a single estimate of a variance was significantly larger than a group of variances. The I 2 statistic describes the degree of heterogeneity across studies' results, with the absence of heterogeneity being defined as I 2 =0%, whereas >0 -50%, >50% and >75% are indicative of low, moderate and high degrees of heterogeneity, respectively 29 . Publication bias was assessed using funnel plots.
Results
Study selection
A total of 556 articles were initially identified using the standardized search terms and the snowball method. Then, all duplicate articles (n=110) were removed, reducing the number of articles to 446. The abstracts, and wherever needed, full-texts, of these 446 articles were assessed for eligibility. 405 articles were excluded based on the exclusion criteria. 7 articles had to be excluded because the variable under investigation was found in less than 3 articles, making a meta-analysis impossible. The factors described in the remaining 34 articles were divided in the following categories: (1) Demographic and general factors at baseline; 26 articles, n = 3,656 participants (2) Clinical factors at baseline; 28 articles, n = 3,949 participants, and (3) Biochemical factors during follow-up; 19 articles, n = 1,781 participants. We allowed for a single article to target multiple categories and subcategories of factors and the same participants were J o u r n a l P r e -p r o o f therefore used for multiple factors. In total, 34 articles (N total = 9,386 participants, of whom N = 2,094 unique participants) were included in the meta-analyses (Figure 1 ). 
Demographic and general factors at baseline
A significant result was found for age, indicating that lower age is associated with better CLZ response (N = 1,247 participants, Hedges' g = 0.142, 95% CI = 0.021 -0.263, P = 0.022; Figure   2a ) with a low degree of heterogeneity (Q = 24.376, I 2 = 9.747). The funnel plot was examined and did not result in suspicion of publication bias (Supplementary figure 1a) . We calculated the mean age of the participants in the included 23 articles for the responders and the nonresponders and found that responders have a mean age (standard deviation) of 35 
Clinical factors at baseline
Schizophrenia paranoid subtype was found to be significantly predictive of good CLZ response (N=424 participants, Hedges' g= 0.259, 95% CI = 0.006 -0.513, P = 0.045; Fig 2b) with no evidence of heterogeneity (Q = 4.690, I 2 = 0.000). The funnel plot was examined and did not result in suspicion of publication bias (Supplementary figure 1b) . As other subtypes may be predictive of response as well, we performed a sensitivity analysis on all subtypes, paranoid vs undifferentiated and paranoid vs disorganized subtype using the same articles we used for the paranoid subtype, if they contained data on other subtypes. For each subtype we found the following numbers: 1) paranoid subtype: total n=176, 63.1% responders; 2) undifferentiated subtype: total n=17, 64.7% responders; and 3) disorganized subtype: total n=36, 52.8% responders. A X 2 test on all subtypes indicated no significant differences between the three subtype (p=.493). X 2 tests between paranoid vs undifferentiated subtype, and paranoid vs disorganized indicated no significant differences (p=.894 and p=.248 respectively) either.
J o u r n a l P r e -p r o o f
Secondly, lower PANSS negative subscores at baseline were associated with better CLZ response (N=133 participants, Hedges' g = 0.719, 95% CI = 0.036 -1.401, P = 0.039; Fig 2c) , with a moderate degree of heterogeneity (Q = 6.079, I 2 = 67.102) and without suspicion of publication bias (Supplementary figure 1c) . For the following factors, no significant results were found: age at SSD onset, age at first hospitalization, number of hospitalizations, duration of illness, length of stay during hospitalizations, BPRS baseline score, CGI baseline score, PANSS total score at baseline, and PANSS positive subscore at baseline (Supplementary table 3) .
Biochemical factors during follow-up
None of these characterisics were associated with clozapine response: serum and plasma concentrations of CLZ and norclozapine (NCLZ), and mean daily CLZ dose (Supplementary J o u r n a l P r e -p r o o f
Discussion
By performing the first meta-analysis on patient characteristics at baseline as potential predictors of clozapine response, we found relatively young age, a low burden of PANSS negative symptoms and paranoid schizophrenia subtype to be significantly associated with better CLZ response. No effects were found for gender, smoking, weight, years of education, marital status, age at SSD onset, age at first hospitalization, number of hospitalizations, duration of illness, length of hospitalizations, overall disease severity, positive symptoms, blood level concentrations or dosing of CLZ.
A possible explanation for the finding that younger age is associated with better CLZ response may be that young patients generally have a relatively short duration of illness and thus less persistent symptoms and as a result may be less resistant to treatment 33 . Although we cannot check this within the current data, in an earlier meta-analysis, which has shown that CLZ prescribed as a first or second-line agent is more efficacious than other antipsychotics 34 , the mean age in all studies was lower [35] [36] [37] [38] [39] than in the study used for the market authorisation of CLZ 10 . Furthermore, most likely, the association between younger age and better treatment response is not CLZ-specific. Interestingly, for 14 out of 23 studies, the mean age for responders was lower than non-responders (some were significant on their own, some were not), 8 out of 23 found an opposite effect and 1 study found equal results. The difference in means (standard deviations) for responders and non-responders were 35.9 (8.4) and 37.2 years (9.3), respectively. This difference is quite small and the standard deviations quite high, so we believe we cannot recommend a certain age as a cut-off when a doctor considers prescribing clozapine, but we do believe age is something that should be taken into account when prescribing clozapine. The message we intend to convey is that younger patients respond better (on average), so when prescribing antipsychotics, it is best not waiting too long with clozapine, especially when have not responded well to other antipsychotics. The association between J o u r n a l P r e -p r o o f lower PANSS negative subscores at baseline and better CLZ response could be explained by the relative specificity of CLZ to target mainly positive symptomsthe relatively disappointing efficacy of antipsychotics in general on negative symptoms has been demonstrated for most antipsychotics 40, 41 . It is important to note that the PANSS negative subscore scale does not only include items about negative symptoms such as blunting of affect and loss of motivation, but also about cognitive symptoms. Therefore, it may be that that when patients have relatively preserved cognitive functioning, they respond to CLZ better. We did not find articles that related cognitive symptoms specifically to CLZ response, so we cannot check whether cognitive symptoms mediate or moderate the result that we found for the PANSS negative subscore.
Interestingly, there was no significant difference between lower (or higher) PANSS positive or total subscores at baseline.
Patients with paranoid schizophrenia subtype showed better response, which is in line with earlier findings for CLZ 41, 42 and first-generation antipsychotics 43 . This could be explained by a previous observation that patients with the paranoid subtype are generally in earlier stages of the disease than patients with non-paranoid subtypes 41 . As another result in this metaanalysis was that younger age is associated with better response, it is possible that the paranoid subtype and younger age are correlated or even converge as one single factor. Our sensitivity analysis on the undifferentiated and disorganized subtype did not reveal significant effects, although this could be due to a lack of power since the number of participants for these subtypes was very low (n=17 and n=36 respectively).
It was unexpected that there was no association between response and CLZ blood levels, as nearly all guidelines define blood levels above 350 ng/ml as important for CLZ response. Most likely, the absence of effect can be explained by a lack of power, as the N was 208 and 252 for the serum and plasma blood level analyses, respectively. Alternatively, the J o u r n a l P r e -p r o o f included studies were observational, not randomized. We hypothesize that there may be patients who are sensible to side effects but respond to fairly low dosages and blood levels (e.g. <300). Those patients would count toward the group of responders with low blood levels. Then, there may be patients who respond poorly but tolerate clozapine well. Clinicians will likely increase the dose to higher blood levels to try and achieve remission, which will work in some but not all patients. In summary, based on the current fairly low sample size and lack of randomized studies (randomizing between levels >350 and <350) we cannot definitely conclude what blood level gives the highest likelihood of response.
There are some limitations of this study. First, there were varying definitions of response, CLZ dosages, treatment times and follow-up time across the studies we included for metaanalyses (Supplementary table 2 summarizes this). Earlier research has shown that approximately 40-50 % of the responders, respond to CLZ within 12 weeks 45, 46 . In studies with relatively short follow-up, possibly not all responders had been identified at the end of study, which could have influenced our results if certain variables are more strongly associated with response in a relatively late stage of a trial than in early trial phases. Second, although the funnel plots did not lead to suspicion of publication bias, we cannot rule out the possibility of publication bias as some studies only reported significant results. Third, it is unclear whether non-responders had been put on therapeutical CLZ dosages as not all studies reported CLZ blood levels. Finally, the effect sizes of the significant factors were small (age: g = 0.14;
paranoid subtype: g = 0.26) to medium (PANSS negative subscore: g = 0.72). No large effects were found. However, most sample sizes were relatively small, which could have led to the small effect sized and false negative results.
In conclusion, this meta-analysis suggests that three easily identifiable demographic and clinical variables (younger age, lower PANSS negative subscores and SCZ paranoid subtype)
